Celularity (CELU) Receivables (2020 - 2025)

Celularity (CELU) posted quarterly Receivables of $116.0 for Q4 2025, down 100.0% quarter-over-quarter from $6.7 million in Q3 2025.

Celularity (CELU) Receivables (2020 - 2025) Analysis & Trends

Celularity (CELU) has reported Receivables for 6 consecutive years, with $116.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Receivables changed N/A year-over-year to $116.0; the TTM figure through Dec 2025 stood at $116.0 (changed N/A YoY), while the FY2025 annual figure was $4.7 million, down 65.68% from the prior year.
Receivables slipped to $116.0 in Q4 2025 per CELU's latest filing, from $6.7 million in the prior quarter.
Across five years, Receivables topped out at $15.8 million in Q1 2024 and bottomed at $116.0 in Q4 2025.
Historically, Receivables has averaged $8.2 million across 5 years, with a median of $7.0 million in 2022.
Annual changes were most pronounced in 2023 — Receivables declined 26.37% — and 2024, when it jumped 206.7%.
Celularity's Receivables stood at $5.2 million in 2021, then soared by 33.12% to $7.0 million in 2022, then surged by 73.96% to $12.1 million in 2023, then dropped by 27.63% to $8.8 million in 2024, then slumped by 100.0% to $116.0 in 2025.
Business Quant data shows CELU's Receivables at $116.0 in Q4 2025, $6.7 million in Q3 2025, and $11.2 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.57 Bn	131.72 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.44 Bn	60.25 Bn	1.37 Bn	1.93 Bn
4	Moderna	60.06 Bn	54.93 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.89 Bn	28.58 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.11 Bn	9.72 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	-
10	Celularity	21.36 Mn	15.19 Mn	-3.27 Mn	4.65 Mn

Download Data